Virtu Financial LLC acquired a new stake in DaVita Inc. (NYSE:DVA – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,229 shares of the company’s stock, valued at approximately $1,140,000.
A number of other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. grew its holdings in DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of DaVita during the fourth quarter valued at about $30,000. Family Firm Inc. purchased a new stake in shares of DaVita during the second quarter worth about $43,000. Versant Capital Management Inc lifted its stake in shares of DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after acquiring an additional 155 shares in the last quarter. Finally, Friedenthal Financial purchased a new position in DaVita in the second quarter valued at about $48,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.
Insider Activity
In other news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the sale, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Javier Rodriguez sold 32,176 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the sale, the chief executive officer now owns 905,659 shares of the company’s stock, valued at approximately $141,219,407.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The disclosure for this sale can be found here. Over the last quarter, insiders sold 173,482 shares of company stock valued at $27,387,069. 2.00% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
View Our Latest Stock Report on DVA
DaVita Price Performance
Shares of NYSE:DVA opened at $163.16 on Thursday. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. The firm has a 50-day simple moving average of $146.25 and a 200 day simple moving average of $140.54. DaVita Inc. has a fifty-two week low of $71.51 and a fifty-two week high of $166.04. The company has a market cap of $14.31 billion, a PE ratio of 18.54, a P/E/G ratio of 0.95 and a beta of 0.87.
DaVita (NYSE:DVA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The business had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.15 billion. During the same quarter last year, the business posted $2.08 EPS. The business’s revenue was up 6.2% on a year-over-year basis. On average, sell-side analysts anticipate that DaVita Inc. will post 9.99 EPS for the current year.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also
- Five stocks we like better than DaVita
- Health Care Stocks Explained: Why You Might Want to Invest
- How Much Can You Make in Stocks in One Month?
- Where Do I Find 52-Week Highs and Lows?
- This Is the Top Large-Cap Stock Insiders Are Buying
- How to Invest in Blue Chip Stocks
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.